1-6 of 6
Elyse R Lopez
Close
Sort by
Journal Articles

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Erin M Dominici, Elyse R Lopez, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Christopher J. Kirk, Ph.D
Journal: Blood
Blood (2013) 122 (21): 1834.
https://doi.org/10.1182/blood.V122.21.1834.1834
Published: 2013
Journal Articles

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL

Lan V Pham, PhD, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Erin M Dominici, Elyse R Lopez, James Pham, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1274.
https://doi.org/10.1182/blood.V122.21.1274.1274
Published: 2013
Journal Articles

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Ph.D, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Michael Wang, MD, Lan V Pham, PhD, Richard J. Ford, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5147.
https://doi.org/10.1182/blood.V122.21.5147.5147
Published: 2013
Journal Articles

Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience

Qingqing Cai, MD, PhD, Yiming Chen, MD., PhD., Dehui Zou, Maria Badillo, BS, Shouhao Zhou, PhD, Liang Zhang, MD, PhD, Elyse R Lopez, Wenqi Jiang, MD, PhD, Hui-qiang Huang, MD, PhD, Tongyu Lin, MD, PhD, Michael Wang, MD
Journal: Blood
Blood (2013) 122 (21): 3056.
https://doi.org/10.1182/blood.V122.21.3056.3056
Published: 2013
Journal Articles

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma

Zhishuo Ou, MD, Lan V Pham, PhD, Muychi T Vang, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Elyse R Lopez, Erin M Dominici, Alex Rollo, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Michael Wang, MD
Journal: Blood
Blood (2013) 122 (21): 3079.
https://doi.org/10.1182/blood.V122.21.3079.3079
Published: 2013
Journal Articles

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

L. Kyle Brett, MD, Mark Axelrod, PhD, Zhishuo Ou, MD, Liang Zhang, MD, PhD, Vicki Gordon, BS, Elyse R Lopez, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Michael J. Weber, PhD, Michael E. Williams, MD, ScM, Michael Wang, MD
Journal: Blood
Blood (2013) 122 (21): 3080.
https://doi.org/10.1182/blood.V122.21.3080.3080
Published: 2013